Genexine Inc (095700):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Genexine Inc (095700) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C7983)・商品コード:DATA904C7983
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:33
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Genexine Inc (Genexine), formerly Genexine Co Ltd is a clinical stage biotechnology company that develops and commercialize immunotherapeutics and next generation novel long-acting biologics. The company develops therapeutic vaccines for incurable diseases and next-generation antibody fusion protein drugs. Its pipeline products include GX-H9, GX-G8, GX-30, GX-188E, GX-17, GX-P2, GX-E2, GX-G3, and GX-G6. Genexine develops products for various therapeutic areas such as orphans, cancers and immune disorders. The company uses hybrid Fc technology platform for the discovery of a wide range of differentiated agonistic protein therapeutics. It partners with other pharmaceutical companies for its research and development activities. The company has operations in the US and South Korea. Genexine is headquartered in Seongnam, South Korea.

Genexine Inc (095700) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Genexine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Genexine Inc, Medical Devices Deals, 2012 to YTD 2018 9
Genexine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Genexine Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Genexine Enters into Licensing Agreement with PharmaJet 11
NeoImmuneTech and Genexine Enter into Agreement with Roche 12
Genexine Enters into Clinical Research Agreement with Merck 13
Tasly Pharma to Form Joint Venture with CBC SPVII and Genexine 14
I-Bridge Capital, Shanghai Tasly Pharma and Genexine Form Joint Venture 15
Kalbe Farma and Genexine Form Joint Venture 16
Genexine and Ilko Ilac Form Joint Venture 17
Licensing Agreements 18
I-Mab Biopharma Enters into Licensing Agreement with Genexine 18
Shanghai ChemoWanbang Biopharma Enters into Licensing Agreement with Genexine 19
Tasly Pharma Enters into Licensing Agreement with Genexine 20
Equity Offering 21
Genexine Raises USD53 Million in Private Placement of Preferred Stock 21
Genexine to Raise USD17 Million in Private Placement of Shares 23
Debt Offering 24
Genexine Raises USD17.8 Million in Private Placement of Bonds 24
Genexine Inc – Key Competitors 25
Genexine Inc – Key Employees 26
Genexine Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Joint Venture 27
Recent Developments 28
Product News 28
07/18/2018: Hyleukin-7 selected as a Korea Drug Development Fund project for combination trial with Merck’s KEYTRUDA 28
06/19/2017: Genexine Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Therapeutic DNA Vaccine, in Combination With KEYTRUDA, for the Treatment of HPV-Induced Cervical Cancer 29
Clinical Trials 30
May 29, 2018: NeoImmuneTech Announces Initiation of HyLeukin-7 Clinical Development for Cancer Patients in the U.S. 30
Apr 03, 2017: Genexine Releases Positive Interim Phase 2 Clinical Data from PGHD Trial with long-acting growth hormone, GX-H9 at ENDO 2017 31
Jan 18, 2017: GX-G6 for Type 2 Diabetes, Receives Phase I IND Approval in Europe 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Genexine Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Genexine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Genexine Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Genexine Inc, Medical Devices Deals, 2012 to YTD 2018 9
Genexine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Genexine Enters into Licensing Agreement with PharmaJet 11
NeoImmuneTech and Genexine Enter into Agreement with Roche 12
Genexine Enters into Clinical Research Agreement with Merck 13
Tasly Pharma to Form Joint Venture with CBC SPVII and Genexine 14
I-Bridge Capital, Shanghai Tasly Pharma and Genexine Form Joint Venture 15
Kalbe Farma and Genexine Form Joint Venture 16
Genexine and Ilko Ilac Form Joint Venture 17
I-Mab Biopharma Enters into Licensing Agreement with Genexine 18
Shanghai ChemoWanbang Biopharma Enters into Licensing Agreement with Genexine 19
Tasly Pharma Enters into Licensing Agreement with Genexine 20
Genexine Raises USD53 Million in Private Placement of Preferred Stock 21
Genexine to Raise USD17 Million in Private Placement of Shares 23
Genexine Raises USD17.8 Million in Private Placement of Bonds 24
Genexine Inc, Key Competitors 25
Genexine Inc, Key Employees 26
Genexine Inc, Other Locations 27
Genexine Inc, Joint Venture 27

List of Figures
Genexine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Genexine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Genexine Inc, Medical Devices Deals, 2012 to YTD 2018 9

★調査レポート[Genexine Inc (095700):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C7983)販売に関する免責事項を必ずご確認ください。
★調査レポート[Genexine Inc (095700):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆